Naranjo, Francisco, JR. .

HRN: 26-81-15  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/05/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
03/05/2025
03/12/2025
IV
600mg
Q8H
Non-healing Wound
Waiting Final Action 
03/05/2025
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
03/05/2025
03/05/2025
IV
4.5g
Now
Non-healing Wound
Waiting Final Action 
03/05/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
03/05/2025
03/26/2025
IV
2.25
Q6H
Non-healing Wound
Waiting Final Action 
03/17/2025
CO-AMOXICLAV 625MG (TAB)
03/17/2025
03/19/2025
PO
625mg
TID
Infected Diabetic Foot
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: